

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

DATE MAILED: 04/23/2002

23

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/736,019	10/22/1996	ANDREW GOODEARL	04585/00200Q	3384
7590 04/23/2002				
KRISTINA BIEKER-BRADY, PH.D. CLARK & ELBING LLP 176 FEDERAL STREET			EXAMINER	
			GUCKER, STEPHEN	
BOSTON, MA 021102214			ART UNIT	PAPER NUMBER
			1647	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary Example 1	ation No. 736, 019 Soodland et al. ner Palen buckle 1647	
—The MAILING DATE of this communication appears on the	cover sheet beneath the correspondence address—	
Pridfr Reply	2	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIR OF THIS COMMUNICATION.	EMONTH(S) FROM THE MAILING DATE	
- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the lift NO period for reply is specified above, such period shall, by default, expire SIX - Failure to reply within the set or extended period for reply will, by statute, cause to the second status. Status Responsive to communication(s) filed on	the statutory minimum of thirty (30) days will be considered timely. ((6) MONTHS from the mailing date of this communication . the application to become ABANDONED (35 U.S.C. § 133).	
 Since this application is in condition for allowance except for forma accordance with the practice under Ex parte Quayle, 1935 C.D. 1 Disposition of Claims 	al matters, prosecution as to the merits is closed in 1; 453 O.G. 213.	
Claim(s) $132, 136-137, +139-143$	is/are pending in the application.	
Of the above claim(s)	is/are withdrawn from consideration.	
□ Claim(s)	is/are allowed.	
\bigcirc Claim(s) 132, 136-137, \vdash 139-14.	is/are rejected.	
Claim(s) 14'3	is/are objected to.	
☐ Claim(s)————————————————————————————————————	are subject to restriction or election requirement.	
Application Papers		
☐ See the attached Notice of Draftsperson's Patent Drawing Review,		
☐ The proposed drawing correction, filed on is ☐ The drawing(s) filed on is/are objected to by	·	
☐ The specification is objected to by the Examiner.		
☐ The oath or declaration is objected to by the Examiner.		
Pri rity under 35 U.S.C. § 119 (a)-(d)		
 □ Acknowledgment is made of a claim for foreign priority under 35 U □ All □ Some* □ None of the CERTIFIED copies of the priorit □ received. □ received in Application No. (Series Code/Serial Number) □ received in this national stage application from the International 	dy documents have been	
*Certified copies not received:		
Attachment(s)	•	
• •	□lat adam Cummer, BTO 440	
 □ Information Disclosure Statement(s), PTO-1449, Paper No(s). □ Notice of Reference(s) Cited, PTO-892 	•••	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	☐ Notice of Informal Patent Application, PTO-152 ☐ Other	
= 1.20 or 2. and processing in an analysis of the second o		

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97) Serial Number: 08/736,019

Art Unit: 1647

Response to Amendment

- 1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 2. Any objections or rejections made in a previous Office Action that are not herein reinstated have been withdrawn.
- 3. Claims 132, 136-137, and 139-142 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 11 of U.S. Patent No. 6,204,241. Although the conflicting claims are not identical, they are not patentably distinct from each other because the polypeptides administered by the process steps recited in the instant application of a method for inducing myelination of a neural cell by a glial cell by using amino acid sequences encoded by SEQ ID NO:154-159 and amino acids 54-103 encoded by SEQ ID NO:150, or amino acids comprising SEQ ID NO:188-189, or amino acids encoded by SEQ ID NO:151, or amino acids 362-411 of SEQ ID NO:170, are polypeptides which are all contained within SEQ ID NO:170 of claim 11 of the instant patent which recites a method for inducing myelination of a neural cell by a glial cell comprising administering amino acids 51-422 of SEQ ID NO:170.

Applicant's arguments filed 2/1/02 have been fully considered but they are not persuasive because Applicant argues that the patented claims do not contain any suggestion to use smaller polypeptide fragments in the method of the instant invention. This is not persuasive because at least one species of each of the rejected instant claims is found within the patented method

Serial Number: 08/736,019

Art Unit: 1647

reciting SEQ ID NO:170 and the instant claims all use open language which encompass the patented claims, i.e. there is no limitation in the rejected claims to exclude them from encompassing the patented claim, so the rejection is maintained. The grounds of this rejection could be obviated by amending the claims to recite closed language that would exclude SEQ ID NO:170 from the instant claims.

- 4. Claim 143 is objected to as being dependent upon a rejected claim.
- 5. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a).
- 6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Page 4

Serial Number: 08/736,019

Art Unit: 1647

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (703) 308-6571. The examiner can normally be reached on Monday to Friday from 0930 to 1800. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623. The fax phone number for this Group is currently (703) 308-4242, but Applicant should confirm this by phoning the Examiner before faxing.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Stephen Gucker

April 22, 2002

GARY'L KUNZ

SUPERVISORY PATENT EXAMINES